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ABSTRACT 
Acid-sensing ion channels (ASICs) are primary acid sensors in the mammalian nervous system 
that are activated by protons under conditions of local acidosis. They have been implicated in 
a range of pathologies including ischemic stroke (ASIC1a subtype) and peripheral pain 
(ASIC1b and ASIC3). Although the spider venom peptide PcTx1 is the best-studied ASIC 
modulator and is neuroprotective in rodent models of ischemic stroke, little experimental work 
has been done to examine its molecular interaction with human ASIC1a or the off-target 
ASIC1b. The complementary face of the acidic pocket binding site of PcTx1 is where these 
channels differ in sequence. We show here that although PcTx1 is 10-fold less potent at human 
ASIC1a than the rat channel, the apparent affinity for the two channels is comparable. We 
  
examined the pharmacophore of PcTx1 for human ASIC1a and rat ASIC1b, and show that 
inhibitory and stimulatory effects at each ASIC1 variant is driven mostly by a shared set of 
core peptide pharmacophore residues that bind to the thumb domain, while peptide residues 
that interact with the complementary face of the biding site underlie species and subtype-
dependent differences in activity that may allow manipulation of ASIC1 variant selectivity. 
Finally, the stimulatory effect of PcTx1 on rat ASIC1a when applied under mildly alkaline pH 
correlates with low receptor occupancy. These new insights into the interactions between 
PcTx1 with ASIC1 subtypes demonstrates the complexity of its mechanism of action, and 
highlights important implications to consider when using PcTx1 as a pharmacological tool to 
study ASIC function. 
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Abbreviations: ASIC, acid-sensing ion channel; CI, confidence interval; BSA, bovine serum 
albumin; PcTx1, psalmotoxin 1; RP-HPLC, reversed-phase high-performance liquid 
chromatography; SSD, steady-state desensitisation; TFA, trifluoroacetic acid. 
 
1. Introduction 
Acid-sensing ion channels (ASICs) belong to the wider superfamily of amiloride sensitive 
degenerin/epithelial sodium channels [1]. They open in response to low extracellular pH such 
as occurs during inflammation and ischemic stroke. There are six main ASIC subtypes (1a, 1b, 
2a, 2b, 3, and 4) with varied tissue expression. They assemble as functional homo- or 
heterotrimeric complexes that have a broad spectrum of pharmacological, and pH-dependent 
gating properties [2, 3]. The ASIC1 splice isoforms, ASIC1a and ASIC1b, are of interest from 
  
a therapeutic perspective in conditions associated with sustained local extracellular acidosis. 
ASIC1a is the predominant isoform expressed in the central nervous system and its inhibition 
is potentially beneficial in several neurological disorders (e.g. ischemic stroke, spinal cord 
injury and multiple sclerosis) [4-7]. In contrast, ASIC1b is expressed primarily in peripheral 
sensory neurons and has been shown to play a role in nociception in rodents [8]. 
 
Several ASIC1 modulators have been discovered ranging from small molecules to larger 
polypeptides, with venom-derived peptides proving the most potent and selective compounds 
to date [9]. The best-studied of these venom peptides is the 40-residue peptide PcTx1 (also 
known as -TRTX-Pc1a), isolated from the venom of the spider Psalmopoeus cambridgei [10]. 
PcTx1 is an inhibitor of rat (r) ASIC1a homomers (IC50 1 nM) and ASIC1a containing 
heteromers (ASIC1a/2b and ASIC1a/2a, IC50 ~3 nM) [11-13], whilst potentiating ASIC1b 
homomers (EC50 ~100 nM) [14]. PcTx1 acts as a gating modifier by binding to the functionally 
important acidic pocket of ASIC1 [15]. The PcTx1:ASIC1 complex structure revealed three 
peptides bound per channel at the subunit interface, with an extensive network of 
intermolecular contacts with both the primary (thumb domain) and complementary (palm and 
 ball) face of the acidic pocket [16]. The functional pharmacophore of PcTx1 at rASIC1a was 
demonstrated by alanine-scanning mutagenesis of PcTx1, in combination with the structure of 
the PcTx1:ASIC1 complex [16, 17], to comprise Trp7, Trp24, Arg26, Arg27, Arg28, and 
Phe30 [18, 19].  
 
Binding of PcTx1 to rASIC1a leads to an increase in the apparent proton affinity of channel 
gating, shifting the steady-state desensitisation (SSD) and activation curves to more alkaline 
values [15]. Under most circumstances this renders channels desensitised and unable to open 
in response to protons, however if desensitisation is not achieved, pH-dependent activation is 
  
enhanced. This mechanism of action was recently shown to be shared for heteromeric 
rASIC1a/2a channels, and proposed to be a more general mechanism by which PcTx1 
modulates ASICs [12]. Evidence for this same mechanism at human (h) ASIC1a is supported 
by the finding that PcTx1 inhibits hASIC1a when applied at pH 7.2 but not at 7.4 [20]. The 
PcTx1 mechanism of action for potentiation of rASIC1b is due to a shift in the activation curve 
to more alkaline values (with little change to the pH-dependence of steady-state 
desensitisation), and a slowing of the desensitisation kinetics of proton-induced currents [14]. 
The different functional outcomes of ASIC1 species and subtype variants upon PcTx1 exposure 
is somewhat surprising given the high level of sequence identity between these channels. 
Human ASIC1a differs from the rat channel at only eight residues, as well as a two-residue 
insertion. Importantly, the only surface-exposed residue in the PcTx1 binding region that 
differs between these channels is Ala178 in rASIC1a, which is a valine in hASIC1a. Rat 
ASIC1a and 1b are splice isoforms that are identical in the C-terminal two-thirds of the protein 
(from residue 186 of rASIC1a onwards). Only a small portion of the overall PcTx1 binding 
region (<30% of crystal contacts) consists of residues before the ASIC1a/1b splice site, with 
crystal contacts observed for residues between 174 and 179 of rASIC1a [17]. In both cases, the 
differences between channels are present on the complementary face of the PcTx1 binding 
region. 
 
Here we present an in-depth analysis of the mechanistic basis for the difference in PcTx1 
potency at human and rat ASIC1a. In addition to the inherent steady-state desensitisation 
characteristics of a channel that give rise to this potency difference, we also probe the molecular 
interactions of PcTx1 with hASIC1a via alanine scanning mutagenesis of the peptide. This scan 
was also performed at rASIC1b and identified potential residues to target in order to manipulate 
PcTx1 subtype selectivity. These insights contribute significantly to our understanding of the 
  
molecular details of the interactions between PcTx1 and ASIC1, and could assist in developing 
PcTx1 or similar peptides as molecular probes and therapeutic lead molecules. 
 
2. Materials and Methods 
2.1 Chemicals and reagents 
Luria-Bertani medium was purchased from Edwards Group (Narangba, QLD, AUS), 
ampicillin from Astral Scientific (Taren Point, NSW, AUS), isopropyl -D-1-
thiogalactopyranoside (IPTG) from Bioline (Aust) (Alexandria, NSW, AUS), acetonitrile from 
Merck (Frenchs Forest, NSW, AUS), trifluoroacetic acid from Chem-supply (Gillman, SA, 
AUS), and Ni-NTA resin, mMessage mMachine cRNA transcription kits and gentamicin 
solution from Thermo Fischer Scientific (Seventeen Mile Rocks, QLD, AUS). TEV protease 
was produced in-house. All other chemicals and reagents were purchased from Sigma-Aldrich 
Australia (Castle Hill, NSW, AUS). 
2.2 Production of PcTx1 and mutants  
Recombinant PcTx1 and mutants were produced using the previously described Escherichia 
coli periplasmic expression system for PcTx1 production [19, 21]. Recombinant PcTx1 
contains a non-native N-terminal serine residue that facilitates TEV cleavage; this addition 
does not change PcTx1 potency at rASIC1a [19], and we do not include it in the residue 
numbering used here. Peptide purity was verified using analytical RP-HPLC and mass 
spectrometry (MS). Peptides were eluted from a Thermo Aquasil C18 column (2.1 × 50 mm, 
5 m) connected to a Shimadzu Prominence UPLC system using a linear gradient of 10–50% 
solvent B (90% acetonitrile, 10% water, 0.043% TFA) over 30 min, at a flow rate of 0.25 
mL/min. Matrix-assisted laser desorption ionisation–time-of-flight (MALDI–TOF) MS was 
performed using a model 4700 Proteomics Bioanalyser (Applied Biosciences). RP-HPLC 
fractions of pure peptides were mixed [1:1 (v/v)] with α-cyano-4-hydroxy-cinnamic acid 
  
matrix (6 mg/mL in 50/50 acetonitrile/water, 0.1% TFA) and MALDI–TOF mass spectra were 
acquired in reflector positive mode. 
 
2.3 Ethics statement  
This study was carried out in strict accordance with the recommendations in the Australian 
code of practice for the care and use of animals for scientific purposes (8th Ed., 2013). The 
protocol for Xenopus laevis studies was approved by the Anatomical Biosciences Animal 
Ethics Committee at The University of Queensland (Approval Number: 
QBI/059/13/ARC/NHMRC and QBI/AIBN/087/16/NHMRC/ARC). Frog recovery surgery 
was performed under anaesthesia (animals bathed in 1.3 mg/mL of MS-222), and all efforts 
were made to minimise suffering. The minimum time between surgeries on the same animal 
was three months, and on the final surgery (maximum of six) frogs were euthanised by 
decapitation under MS-222 and ice anaesthesia. 
 
2.4 Xenopus laevis oocyte electrophysiology 
Two-electrode voltage clamp (TEVC) electrophysiology was carried out using Xenopus 
oocytes as previously described [22]. cRNA encoding rASIC1a, rASIC1b, and hASIC1a was 
synthesised using an mMessage mMachine cRNA transcription kit and healthy stage V-VI 
oocytes injected with 0.5–4 ng cRNA per cell. All experiments were performed at room 
temperature (19–21°C) in ND96 solution (96 mM NaCl, 1.0 mM CaCl2, 2 mM KCl, 2 mM 
MgCl2, 5 mM HEPES, pH 7.45). Data in Figures 5 and 6 were performed in ND96 solution 
with the aforementioned composition, however only the CaCl2 concentration was different at 
1.8 mM. HEPES was replaced by MES to buffer solutions at pH<6.8. Oocytes were stored at 
17 C in ND96 solution supplemented with 25 g/mL gentamicin, 25 g/mL streptomycin, 
  
and 2.5% horse serum. Solutions in the presence of PcTx1 contained 0.1% fatty acid free-
bovine serum albumin (BSA) to prevent adsorption to plastic ware and tubing.  
 
Data were collected using an Axoclamp 900A amplifier (Molecular Devices, Sunnyvale, CA, 
USA) controlled by a pClamp data acquisition system (Axon Instruments, Union City, CA, 
USA). Voltage and current electrodes were filled with 3 M KCl, and the resistance of both 
electrodes was 0.5–1.0 MΩ. Whole-cell currents from oocytes were recorded 1–3 days after 
injection, with oocytes clamped at –60 mV and currents elicited by a pH drop as indicated in 
each figure (digitized 5 kHz and filtered at 0.01 Hz). Changes in extracellular pH were induced 
using a microperfusion system that allowed local rapid exchange of solutions (bath volume 
~30 L). 
 
2.5 Data and statistical analysis 
Current traces were analysed using pClamp10, with desensitisation kinetics fit with a single 
exponential function. All other data fitting and statistical analyses were carried out using Prism 
7.03 (GraphPad Software, San Diego, CA, USA). The Hill equation was fitted to normalised 
concentration-response data to obtain the concentration of half-maximal response (pEC50, 
pIC50 or pH50). Mean values for EC50, and IC50 are presented as nM for readability, while the 
distribution of data as 95% confidence intervals (CI) are presented for the pEC50, pIC50 as 
calculated when fitting accumulated data to logistic equations in GraphPad Prism. 
Concentration-response curves were compared via logIC50 values with an extra sum-of-squares 
F test (two-groups) or one-way ANOVA with Bonferroni correction for multiple comparisons 
(> two groups); in each case a Gaussian distribution and equal standard deviations were 
assumed. Data with a single concentration were compared with a one-way ANOVA with 
Dunnett’s test for comparison to a particular mean (wild-type value). Intercepts of linear 
  
regressions (Schild plot) were compared with an Analysis of Covariance (ANCOVA). All data 
points are shown as mean ± SEM (standard error of the mean), the number of replicates (n) 
represent separate experimental oocytes, and P < 0.01 was considered to be significant for all 
data. 
 
3. Results 
3.1 PcTx1 is less potent against hASIC1a than the rat isoform 
Using pure recombinant peptide, we found that PcTx1 applied at pH 7.45 inhibits hASIC1a 
expressed in Xenopus oocytes with an IC50 of 3.2 nM (pIC50 95% CI 8.40–8.59), that is ~10-
fold and significantly lower (P < 0.0001) compared to its inhibition of rASIC1a (pIC50 95% CI 
9.44–9.56) under the same conditions (Fig. 1B and C). This is consistent with a previous report 
that the same dilution of PcTx1 venom is substantially less effective at hASIC1a than the mouse 
isoform [20]. In order to assess if this was due to species differences in the binding site, we 
tested PcTx1 activity at the “humanised” rASIC1a channel (i.e., A178V mutant). This 
substitution is the only surface-exposed residue in the PcTx1 binding region of the channel that 
differs between rat and human ASIC1a (Fig. 1A). PcTx1 was equipotent against wild-type 
rASIC1a and the A178V mutant (pIC50 95% CI 9.42–9.60; P = 0.8168) (Fig. 1B).  
 
Having discounted a direct interaction as the basis for the 10-fold difference in potency of 
PcTx1 against rat and human ASIC1a, we analysed the effect of conditioning pH (via steady-
state desensitisation curves) on PcTx1-mediated inhibition of ASIC1a. Desensitisation of the 
channel is a process linked closely with inhibition because if all channels become desensitised, 
they are no longer available to open and conduct current. Figure 1D shows the steady-state 
desensitisation curves for rASIC1a, rASIC1a A178V, and hASIC1a (see Table 1 Control 
values for 95% CI). Desensitisation of hASIC1a is significantly less sensitive to protons than 
  
rASIC1a (P < 0.0001) and introduction of a A178V mutation in rASIC1a has no effect on the 
pH-dependence of SSD (P = 0.7098). 
 
We then assessed the effect of four different concentrations of PcTx1 on the pH-dependence 
of steady-state desensitisation of rat and human ASIC1a, as well the rASIC1a A178V mutant 
(Fig. 2A–C; Table 1). Increasing the PcTx1 concentration increased the alkaline shift in pH50, 
with the degree of shift being relatively similar for all three channels at a given PcTx1 
concentration. To better assess the relative affinity of PcTx1 for each channel this data was 
used to construct a Schild Plot. Specifically, the pH50 ratios (in the absence and presence of 
peptide) for each concentration of PcTx1 were used and the pA2 interpolated from the abscissa 
intercept of the graph (Fig. 2D). This analysis yielded pA2 values of 8.43, 8.49 and 8.60 for 
rASIC1a, rASIC1a A178V, and hASIC1a, respectively. A pA2 value represents the negative 
log of the concentration of antagonist that results in a two-fold shift in the agonist response 
curve and represents the affinity of the antagonist for the receptor. The values obtained here 
for rASIC1a, rASIC1a A178V, and hASIC1a correspond to PcTx1 concentrations of 3.72, 3.21 
and 2.54 nM, respectively. The similarity of the pA2 values suggests that there is essentially 
no difference in the affinity of PcTx1 for the human and rat channels (P = 0.8474). This further 
supports our hypothesis that the difference in proton sensitivity of steady-state desensitisation 
between the rat and human channel explains the apparent species-dependent difference in 
potency of PcTx1. 
 
The PcTx1-mediated functional effect and on-rate at rASIC1a are pH dependent (Fig. 2E). 
PcTx1 application for 5 s at pH 7.45 and above resulted in potentiation of currents, whereas 
inhibition was observed at pH 7.30. This demonstrates that under all conditions, the interaction 
and functional effect of PcTx1 is extremely rapid. For a conditioning pH of 7.75 (an alkaline 
  
shift of 0.42 units from pH50 of steady-state desensitisation), no inhibition was observed even 
with constant perfusion of 3 nM PcTx1 for 10 min. The recovery from PcTx1 action is also pH 
dependent, with a faster off-rate when conditioning and washing are at higher pH (Fig. 2F). 
 
Given the pH dependence of the on- and off-rate, we next assessed the potency of PcTx1 when 
applied at different conditioning pHs (Fig. 3; Table 2). As expected from the SSD data in Figure 
2, application of the peptide at more acidic conditioning pH results in more potent activity for 
all channels. Comparison of rat and human IC50 values at a given shift in pH from the pH50 SSD 
for each channel reveals equipotent activity in agreement with the Schild plot (P = 0.2946 for 
pIC50 comparison of rASIC1a at pH 7.6 with hASIC1a at pH 7.3). As the conditioning pH 
becomes more alkaline, there is a point at which PcTx1 is no longer an inhibitor of channels. 
With a further increase in the conditioning pH, PcTx1 indeed potentiates ASIC1a currents in a 
concentration-dependent manner in agreement with the on-rate studies at pH 7.75. 
 
3.2 Pharmacophore of PcTx1 against hASIC1a 
To further study potential differences in modulation of rat and human ASIC1a by PcTx1, we 
performed an alanine scan at hASIC1a to determine the PcTx1 functional pharmacophore. The 
PcTx1 binding surface for activity at both channels is very similar, with mutation of the key 
pharmacophore residues as determined on rASIC1a [18, 19] also resulting in a loss of inhibition 
at hASIC1a (Fig. 4A–E; Table 3). However, despite the near identity of the binding site 
between the species isoforms, some differences were observed. Deletion of two N-terminal 
residues of PcTx1 (N2) resulted in a mild loss of activity of at the human channel (P = 0.0001) 
but had no effect on activity at the rat channel (P = 0.9995), suggesting the N-terminus is more 
important to hASIC1a activity (Fig. 4F). Mutation of Lys25 to an alanine (K25A) had little 
effect on the IC50 for human and rat ASIC1a, however the inhibition was never complete at 
  
hASIC1a with <75% inhibition even at saturating concentrations, whereas it retained full 
efficacy at the rat channel (Fig. 4G). The R27A mutant lost a similar degree of potency at both 
rat and human ASIC1a . However, similar to the K25A mutant, the efficacy of R27A at 
hASIC1a was incomplete and saturated at ~80% inhibition, whilst it retained full efficacy on 
the rat channel (Fig. 4H).  
 
3.3 Pharmacophore of PcTx1 at rat ASIC1b 
We also assessed the activity of our series of PcTx1 alanine mutants at rASIC1b in order to 
determine if the pharmacophore residues were the same as for rASIC1a. PcTx1 is a potent 
potentiator of rASIC1b with an EC50 of 24.6 nM , ~30-fold higher than the IC50 for inhibition 
of rASIC1a (Fig. 5A). The ability of each PcTx1 mutant to potentiate rASIC1b was assessed 
using two concentrations selected from the slope of the wild-type peptide concentration-
response curve and compared to the relative change in activity of these mutants at rASIC1a 
(Fig. 5B–D). Mutation of PcTx1 residues that compose the primary pharmacophore residues 
at rASIC1a had an equally deleterious effect on its activity at rASIC1b. In contrast, alanine 
mutations to Lys25 and Thr37, which had minimal effect on rASIC1a activity, decreased 
activity at rASIC1b. Conversely, the C3 truncation showed a loss of rASIC1a activity with 
no change to the potentiation of rASIC1b. The potentially improved selectivity of PcTx1 K25A 
and T37A mutants towards rASIC1a was confirmed upon obtaining full concentration-
response curves which revealed apparent effects on both the efficacy and potency at rASIC1b 
(Fig. 6B and C; Table 4). In addition to the individual mutations, a double mutant 
(K25A/T37A) showed a further decrease in rASIC1b activity (P = 0.0182) with little effect on 
rASIC1a potency (P = 0.5466), thus has ~3 to 4-fold improved rASIC1a selectivity compared 
to wild-type peptide. Finally, we also assessed the effect of mutating residues Trp24 and Arg28 
as they are key pharmacophore residues for PcTx1 inhibition of rASIC1a. These residues are 
  
different in Hi1a (Fig. 6A), a peptide with substantial similarity to PcTx1 and is a subnanomolar 
inhibitor of rASIC1a but only a weak potentiator of rASIC1b (~130% of control at 1 μM) [5]. 
Unfortunately none of the tested mutations to residues 24 and 28 of PcTx1 improved ASIC1a 
selectivity, while also retaining suitable potency (Fig. 6B and C; Table 4). Intriguingly, the 
W24F and W24Y mutants showed an incomplete block at rASIC1a at saturating 
concentrations, similar to what is observed for Hi1a, which contains a Tyr at position 24.  
 
4. Discussion 
The tarantula peptide PcTx1 was the first potent and selective ASIC1 modulator to be 
discovered [10], making it one of the most widely used tools to study ASIC function in vitro 
and in vivo. Nevertheless, the details of how it interacts with several ASIC1 variants to produce 
different species and subtype-dependent activities is far from clear. Here we show that despite 
highly similar binding sites on rASIC1a, rASIC1b and hASIC1a, PcTx1 can have subtly (rat 
and human ASIC1a) or substantially (rASIC1a and rASIC1b) different functional 
consequences on these channels. In addition, we show that mutations of PcTx1 residues (i.e. 
Lys25) facing the complementary binding surface may be able to be exploited to modify the 
species and subtype selectivity of the peptide. 
 
A recent proposal for the mechanism of ASIC gating involves a linear activation model with 
channel opening requiring multiple protons to bind to the resting state, and desensitisation 
arising exclusively from the open state [23]. During proton-dependent activation the sequential 
protonation events brings carboxylate pairs between the thumb and finger/palm domains closer 
together. With each protonation, this pinching motion is made more energetically favourable 
(high cooperativity of gating) as it draws unprotonated neighbouring residues closer together 
[24-26]. This gating rearrangement is consistent with structural studies that revealed an 
  
expanded acidic pocket in the resting state compared to that of the open and desensitised states 
[27]. In the continued presence of protons, ASICs undergo desensitisation. This provides a 
technical limitation, as if the kinetics of desensitisation are faster than the application of protons 
to all channels being studied, the overlap of ASIC desensitisation will likely mask the true 
extent of proton-induced activation. ASICs also undergo steady-state desensitisation when 
channels are subjected to mildly acidic conditions (pH 7.4–6.9) that do not induce an 
observable current, however this transitions the channel to a desensitised state that can no 
longer activate in response to a low pH-stimulus.  
 
The majority of experimental data published on ASIC modulators has involved the use of 
rodent channels. To our knowledge this is the first report of a concentration-response curve for 
PcTx1 activity at hASIC1a under physiological conditions (pH ~7.45), where we show a 10-
fold decrease in activity at the human channel compared to the rat channel. Species-dependent 
potency of PcTx1 and other ASIC modulators has implications for their use and development 
as pharmacological tools and therapeutic candidates. In the case of PcTx1, the species-
dependent potency has little to do with the differences at residue 178, despite this being the 
only change to the PcTx1 binding region between rat and human ASIC1a. The fact that this 
mutation is insufficient to cause a change in the interaction and the functional consequences of 
PcTx1 binding suggests that the observed species difference in potency is due to the mechanism 
of action of the peptide as opposed to a difference in binding interaction.  
 
PcTx1 inhibits rASIC1a by shifting the steady-state desensitisation curve to more alkaline 
values, thereby rendering channels desensitised at physiological pH [15]. However, some 
aspects of its mechanism of action and binding mode remain unclear. This mechanism of action 
is the reason for the 10-fold difference in potency we observed between human and rat ASIC1a. 
  
Specifically, when applied at pH 7.45 (or the pH50 SSD + 0.12) in order to produce 50% 
desensitisation of rASIC1a, PcTx1 only needs to cause a shift of 0.1 pH units in the alkaline 
direction, whereas under the same conditions for hASIC1a (pH50 SSD 7.04) this would require 
a shift of 0.41 pH units, and consequently a higher concentration of PcTx1. Our data extends 
the findings Sherwood and Askwith who tested the activity of P. cambridgei venom (at 
1:10,000 dilution) at pH 7.2 and 7.4 at both human and mouse ASIC1a, and only observed 
inhibition of hASIC1a at pH 7.2 [20]. The use of whole venom in this study confounds 
interpretation of the data, as other molecules in the venom might have activity at either rat 
and/or human ASIC1a. P. cambridgei venom is known to be a mixture of many molecules, 
with PcTx1 contributing <0.5% to the total venom [28]. Sherwood and Askwith also showed 
that the hASIC1a AKPDL mutant (A274S/P285S/K291N/D298/L299 to mimic rASIC1a) 
recapitulated both the PcTx1-induced (using P. cambridgei venom) inhibition at pH 7.4 and 
pH-dependent steady-state desensitisation properties of wild-type mouse ASIC1a [20]. 
Together this shows that the apparent potency of PcTx1 is dependent on the pH at which it is 
applied — the closer to the pH50 of steady-state desensitisation, the higher the apparent potency 
for inhibition.  
 
The reported effect of PcTx1 at rat and mouse ASIC1a when channels are preconditioned at 
high pH (7.9 or 8.0) is contradictory, with some studies finding concentration-dependent 
inhibition [13, 29] and others showing either no observable activity or potentiation of proton-
gated currents [15]. By performing full SSD curves for both rat and human ASIC1a in the 
presence of varying concentrations of PcTx1, we demonstrated that PcTx1 is a concentration-
dependent potentiator of pH 6-evoked currents when applied at high pH (>7.75). Consistent 
with this, we see no inhibition at pH 7.75 even after 10 min of application, which indicates that 
PcTx1 is unable to induce the desensitised state under these conditions. Specifically, the 
  
peptide alone cannot force the channel to undergo conformational rearrangement from the high 
pH resting state (without protons bound) to the non-conducting desensitised state. When PcTx1 
is applied at high pH the positively charged side chains of the peptide may act in a similar 
manner to protons and interact with ASICs to assist in the cooperativity of pH-dependent 
gating, but not enough that channels enter a desensitised state, ultimately resulting in enhanced 
low pH-evoked currents. It is also important to consider the occupancy of the three PcTx1 
binding sites on the channel, and that the binding affinity appears to become lower as pH 
increases [29]. We propose that at pH >7.7 and at high enough concentrations of PcTx1, the 
peptide binds the majority of channels but with only partial occupancy of the three intra-
channel sites and gives rise to potentiation. This is in agreement with the potentiation effect at 
rASIC1a being observed at PcTx1 concentrations >3 nM at pH 7.75, whereas inhibition is 
achieved at ~30-fold lower concentrations when in the presence of co-operating protons. This 
is further supported by our results showing slower on- and off- rates at high pH, consistent with 
a smaller number of peptide-channel interactions.  
 
Our data suggest that at pH 7.6 and below, enough protonation events have occurred that 
rASIC1a is in a conformation/state of surface charge where the PcTx1 off rate is sufficiently 
slowed that more binding sites per channel are occupied at a given time and can stabilise the 
desensitised state, thereby giving rise to inhibition of current. The more protons bound, the 
more favourable the channel conformation for PcTx1 binding as it is structurally closer to the 
desensitised state, thus the higher occupancy and inhibitory potency (see Fig. 3). This is in 
agreement with early I125-PcTx1 binding studies to rat brain and rASIC1a overexpressed in 
CHO cells [29]. This study revealed a bell curve of binding that was maximal at ~pH 7, with 
>90% of maximal binding occurring between pH 5.75 and 7.75. The initial potentiation of 
currents observed with a 5 s application of PcTx1 at pH 7.45 and 7.6, as seen in Figure 2E, 
  
supports our suggestion that partial occupancy of the three PcTx1 binding sites results in 
potentiation, while higher binding site occupancy results in channel desensitisation and 
functional inhibition.  
 
PcTx1 has also been shown to stabilise the open state of ASIC1a, however with lower affinity 
than for the desensitised state. Binding to the open state was initially shown by application of 
PcTx1 at pH 7.1 inducing rASIC1a currents, whereas pH 7.1 alone does not open these 
channels [14]. A concentration-response curve using this application protocol revealed a lower 
limit for the EC50 of 156 nM. The true EC50 for the open state is hard to determine, as a plateau 
in maximal response was not reached, as well as current desensitisation likely masking 
complete activation. Nevertheless, this is in agreement with the notion that PcTx1 can function 
in a similar manner to protons to modulate ASICs, and that the binding event can be rapid. 
Although studying different steps in the linear kinetic model, together these studies suggest 
that PcTx1 can bind multiple ASIC1a states, however binding to the desensitised state is 
preferred.  
 
Although the ability of PcTx1 to act on ASIC1a in a similar manner to protons can explain the 
difference in observed potency of PcTx1 for human and rat ASIC1a, our PcTx1 alanine scan 
showed that there are subtle difference in the pharmacophore residues for each species variant. 
Given the significant state-dependent rearrangements of the acidic pocket where PcTx1 binds 
[27, 30, 31], it is conceivable that PcTx1 makes subtly different peptide:channel interactions 
to what has been shown with electrophysiology at pH 7.45 [18, 19] as well as in the co-crystal 
structures where the extracellular domain is most similar to the desensitised state [16, 17]. 
Species-dependent differences in activity of PcTx1 N2, K25A, and R27A variants suggest 
that these regions play different roles in the overall binding kinetics/mechanism of PcTx1 to 
  
these isoforms of ASIC1a. It is intriguing to note that in the crystal structure of PcTx1:ASIC1, 
Lys25 and Arg27 of PcTx1 make contacts almost exclusively with the complementary face (13 
of 14 combined contacts) of the acidic pocket where the single A178V mutation lies. This 
highlights the potential to perform further mutagenesis at these positions in PcTx1 in an attempt 
to further alter species-dependent ASIC1a activity. Given the conditioning pH was kept 
constant at 7.45, both species variants would be present in the resting state, however at a 
different stage on the linear model with a different amount of protonation sites occupied. 
 
Although PcTx1 is widely used as a selective ASIC1a inhibitor, its significant potentiating 
activity on ASIC1b (Fig. 5A) might confound any observed findings when used in vivo or on 
primary cells. Thus, having more subtype-selective tools would be of great value. The 
extensive overlap in pharmacophore across rASIC1a and rASIC1b was of some surprise given 
the different functional consequence of PcTx1 application at these subtypes [14, 15]. However, 
the overall orientation of the PcTx1 binding region of ASIC1 is extremely similar in the 
desensitised and open state structures giving credence to our results [30, 31]. The functional 
importance of channel residues that differ between rASIC1a and rASIC1b that are both pre-
splice site and crystal contacts have been studied for Hm3a (82% identity with PcTx1) [32]. 
Within this region, the rASIC1a mutants R175C and E177G (rASIC1a to ASIC1b 
substitutions) caused a 10–20-fold loss in inhibitory activity by Hm3a. These residues on the 
complementary surface are indeed in close proximity with PcTx1 residues 24–28. Here we 
produced a double mutant of PcTx1 (K25A/T37A) with slightly improved selectivity for 
rASIC1a inhibition over rASIC1b potentiation compared to the wild-type peptide. The W24Y 
and R28H mutants (PcTx1 to Hi1a mutations) did not improve selectivity, suggesting either 
the second half of Hi1a, or the different mechanism of action and binding orientation of the 
double-knot peptide compared to PcTx1 is responsible for its more pronounced ASIC1a 
  
selectivity. The incomplete inhibition of PcTx1 W24F and W24Y at rASIC1a (similar to Hi1a) 
could be explained by interactions from this residue destabilising the open-to-desensitised 
gating step. Although the mutant peptides made here did not result in any more species- or 
subtype-selective PcTx1 analogues, this work highlighted that residues interacting with the 
complementary face of ASIC1 can likely be targeted for further mutagenesis to develop more 
selective PcTx1 analogues. 
 
In summary, we show that the different apparent potency of PcTx1 on rat and human ASIC1a 
is due to variations in their inherent pH-dependence of steady-state desensitisation, rather than 
differences in the PcTx1 binding affinity or differences in the ASIC1a acidic pocket. The 
functional outcome observed depending on PcTx1 application pH is an important point for 
consideration when using the peptide as a pharmacological tool to study ASICs, particularly in 
vivo where the exact pH under which the peptide is acting, and how rapidly this pH changes, 
is often not known. Furthermore, alanine-scanning mutagenesis revealed subtle differences in 
the PcTx1 pharmacophore at rASIC1a, hASIC1a, and rASIC1b. It would be valuable in future 
studies to develop PcTx1 analogues that are more selective for specific ASIC variants and 
activities, as they would add to the toolkit of pharmacological modulators available to 
understand the wide diversity of ASIC functions. 
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Tables:  
Table 1 
Effect of increasing concentrations of PcTx1 on steady-state desensitisation properties
1
. 
Condition rASIC1a hASIC1a rASIC1a A178V 
Control 7.33 (7.33–7.34) 7.04 (7.04–7.05) 7.34 (7.32–7.35) 
0.35 nM PcTx1 7.46 (7.45–7.46) 7.13 (7.12–7.14) 7.45 (7.44–7.47) 
1 nM PcTx1 7.52 (7.51–7.53) 7.23 (7.21–7.24) 7.55 (7.54–7.57) 
3.5 nM PcTx1 7.64 (7.63–7.66) 7.43 (7.41–7.45) 7.66 (7.65–7.68) 
10 nM PcTx1 7.72 (7.69–7.76) 7.54 (7.53–7.55) 7.73 (7.71–7.75) 
1
 Shown are pH50 values and 95% confidence intervals in brackets. 
 
Table 2 
Activity of PcTx1 at different conditioning pH
1
. 
Condition rASIC1a hASIC1a rASIC1a A178V 
pH 7.60 8.73 (8.64–8.82) N/A 8.84 (8.74–8.95) 
pH 7.45 9.48 (9.42–9.55) 8.48 (8.42–8.54) 9.45 (9.37–9.53) 
pH 7.30 9.81 (9.39–10.24) 8.79 (8.73–8.85) 9.67 (9.31–10.02) 
pH 7.20 N/A 9.09 (9.01–9.17) N/A 
1
 Shown are pH50 values and 95% confidence intervals in brackets. 
 
Table 3 
Summary of wild-type and mutant PcTx1 IC50 values on rat and human ASIC1a 
  Human   Rat
1
 
 IC50 (nM) pIC50 
(95% CI) 
P value
2
  IC50 (nM) pIC50 
(95% CI) 
P value
2
 
WT 3.14 8.50 
(8.41–
8.60) 
–  0.35 9.45 
(9.34–
9.55) 
– 
N2 22.4 7.65 
(7.51–
7.78) 
0.0001  0.47 9.33 
(9.18–
9.47) 
0.9995 
K6A >1000 N/A 0.0001  34.2 7.47 
(6.96–
7.98) 
0.0001 
W7A >1000 N/A 0.0001  >1000 N/A 0.0001 
  
K8A 5.23 8.28 
(8.18–
8.38) 
0.2676  0.59 9.23 
(9.13–
9.33) 
0.9991 
H14A 4.31 8.37 
(8.22–
8.50) 
0.7897  0.26 9.62 
(9.49–
9.76) 
0.9994 
W24A >1000 N/A 0.0001  90.6 7.04 
(6.46–
7.63) 
0.0001 
K25A 4.98 8.32 
(8.14–
8.46) 
0.5242  0.64 9.19 
(9.10–
9.29) 
0.9991 
R26A
3
 164 6.79 
(6.25–
7.01) 
0.0001  1880 N/A 0.0001 
R27A 33.1 7.48 
(7.42–
7.54) 
0.0001  3.01 8.52 
(8.46–
8.59) 
0.2000 
R28A 106 6.98 
(6.84–
7.07) 
0.0001  5.06 8.30 
(8.23–
8.36) 
0.0293 
S29A 3.30 8.48 
(8.40–
8.56) 
0.9997  0.32 9.49 
(9.45–
9.53) 
0.9999 
F30A3 25.6 7.59 
(6.97–
8.22) 
0.0001  6.79 8.17 
(7.55–
8.79) 
0.0208 
E31A 3.00 8.52 
(8.42–
8.62) 
0.9997  0.76 9.12 
(9.07–
9.17) 
0.9948 
V32A 63.3 7.20 
(6.83–
7.39) 
0.0001  6.27 8.20 
(8.13–
8.28) 
0.0589 
V34A 2.09 8.68 
(8.54–
8.82) 
0.4592  0.49 9.31 
(9.17–
9.45) 
0.9995 
P35A 4.24 8.37 
(8.26–
8.48) 
0.9445  0.13 9.89 
(9.84–
9.95) 
0.8977 
K36A 4.99 8.30 
(8.24–
8.37) 
0.3038  0.19 9.72 
(9.66–
9.79) 
0.9957 
  
T37A 7.69 8.11 
(8.05–
8.18) 
0.0033  0.25 9.60 
(9.48–
9.72) 
0.9995 
P38A 10.8 7.97 
(7.80–
8.13) 
0.0001  1.36 8.86 
(8.74–
8.99) 
0.6950 
C3 8.77 8.06 
(7.96–
8.15) 
0.0005  1.44 8.84 
(8.74–
8.93) 
0.4434 
1
 Values for rat ASIC1a not from this study are from [18, 19], 
#
 
2
 P values are compared to WT PcTx1 for each species variant and bold indicates a significant 
difference (P < 0.01). 
3
 Mutants that potentiate channel and values indicate EC50.  
 
Table 4 
Summary of wild-type and mutant PcTx1 pIC50 values on rat ASIC1a and ASIC1b 
 rASIC1a  rASIC1b 
 pIC50 (95% CI) P value  pIC50 (95% CI) P value 
WT 9.05 (8.98–9.14) –  7.61 (7.40–7.82) – 
 9.14 (9.03–9.26) 0.2090  7.37 (7.11–7.62) 0.1341 
T37A 9.27 (8.99–9.49) 0.1694  7.63 (7.34–8.01) 0.8923 
K25A/T37A
1
 9.02 (8.94–9.12) 0.5466  7.00 (6.57–7.43) 0.0108 
W24A 6.72 (6.35–6.93) 0.0001  N/A N/A 
W24F 6.64 (6.40–6.84) 0.0001  6.76 (6.48–6.97) 0.2601 
W24Y 7.50 (7.22–7.79) 0.0001  7.28 (7.11–7.44) 0.0166 
R28H 9.06 (8.92–9.20) 0.9697  7.44 (7.13–7.78) 0.3912 
 
Figure legends: 
Fig. 1. Comparison of PcTx1 activity at rat and human ASIC1a. (A) Structure of cASIC1 with PcTx1 
bound at the acidic pocket (PDB code 4FZ0). The position of residue 178 is highlighted in red. (B) 
Example current traces for PcTx1 concentration-response (left) and steady-state desensitisation (right) 
curves for rat (black) and human (blue) ASIC1a. Scale bar shown in grey: abscissa 3 s, ordinate 1000 
  
nA. (C) Concentration-response and (D) steady-state desensitisation curves for rASIC1a, hASIC1a, and 
the humanised A178V mutant of rASIC1a. Data points represent mean ± SEM (n = 4–7). 
 
Fig. 2. pH-dependent effects of PcTx1 on ASIC1a. Effect of increasing concentrations of PcTx1 on the 
steady-state desensitisation of (A) rASIC1a, (B) hASIC1a, and (C) rASIC1a A178V. Control currents 
were taken from pH 7.45 to pH 6, with all data normalised to this peak. (D) Schild plot for inhibition 
of ASIC1a showing no significant difference in ordinate intercepts for each channel (P = 0.8474, F = 
0.169, DFn = 2, DFd = 8). (E) Time course of rASIC1a inhibition by 3 nM PcTx1 with variable 
conditioning pH. Right panel is zoomed into the first 30 s of the on-rate graph. (F) Recovery of rASIC1a 
from inhibition by 3 nM PcTx1 (110 s application) at different conditioning pH. Data points represent 
mean ± SEM (n = 4–7). 
 
Fig. 3. Activity of PcTx1 at different conditioning pHs. (A) Example current traces of PcTx1 
concentration-response data for rat (top) and human (bottom) ASIC1a conditioned at pH50 SSD + 0.26–
0.27 pH units. Scale bar shown in grey: abscissa 3 s, ordinate 1000 nA. Data for (B) rASIC1a, (C) 
hASIC1a, and (D) rASIC1a A178V. Data points represent mean ± SEM (n = 4–7). 
 
Fig. 4. Structure-activity relationship of PcTx1 at hASIC1a. (A-D) Concentration-response curves for 
modulation of human ASIC1a by WT and mutant PcTx1. (E) Mean ± SEM pIC50 values, and dashed 
line represents WT pIC50 value. Bold and italicised mutants represent a loss of activity compared to WT 
(one-way ANOVA with Dunnett’s test: F = 152.4, P < 0.001). (F-H) Comparison of rat and human 
concentration-response curves for PcTx1 WT, N2, and K25A. Data points represent mean ± SEM (n 
= 3–6). 
 
Fig. 5. Comparative activity of PcTx1 mutants at rASIC1a and rASIC1b. (A) Concentration-response 
curves for wild-type PcTx1 at rASIC1a and rASIC1b. Scale bar shown in grey (abscissa 3 s, ordinate 
1500 nA). (B) Example current traces for PcTx1 WT, K25A, and T37A peptides at rASIC1a and 
  
rASIC1b. (C) Relative activity of PcTx1 analogues compared to wild-type PcTx1 for inhibition of 
rASIC1a (red circles) and potentiation of rASIC1b (black squares) at a conditioning pH of 7.45. Grey 
shading indicates mutants where the change in activity was different between ASIC1a and ASIC1b for 
that variant. rASIC1a activity for the R26A and F30A mutants are not shown as they potentiate rather 
than inhibit this channel. Data points represent mean ± SEM (n = 3–5). 
 
Fig. 6. Subtype specificity of PcTx1 analogues. (A) Amino acid sequence alignment of the ASIC1 
modulating peptides PcTx1 and Hi1a. Differences in sequences are indicated by grey boxes, and the 
pharmacophore residues for PcTx1 activity at rASIC1a are denoted by red dots. Concentration-response 
curves for PcTx1 mutants at (B) rASIC1a and (C) rASIC1b. Data points represent mean ± SEM (n = 
3–5). 
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Tables:  
Table 1 
Effect of increasing concentrations of PcTx1 on steady-state desensitisation properties
1
. 
Condition rASIC1a hASIC1a rASIC1a A178V 
Control 7.33 (7.33–7.34) 7.04 (7.04–7.05) 7.34 (7.32–7.35) 
0.35 nM PcTx1 7.46 (7.45–7.46) 7.13 (7.12–7.14) 7.45 (7.44–7.47) 
1 nM PcTx1 7.52 (7.51–7.53) 7.23 (7.21–7.24) 7.55 (7.54–7.57) 
3.5 nM PcTx1 7.64 (7.63–7.66) 7.43 (7.41–7.45) 7.66 (7.65–7.68) 
10 nM PcTx1 7.72 (7.69–7.76) 7.54 (7.53–7.55) 7.73 (7.71–7.75) 
1
 Shown are pH50 values and 95% confidence intervals in brackets. 
 
 
 
 
Table 2 
Activity of PcTx1 at different conditioning pH
1
. 
Condition rASIC1a hASIC1a rASIC1a A178V 
pH 7.60 8.73 (8.64–8.82) N/A 8.84 (8.74–8.95) 
pH 7.45 9.48 (9.42–9.55) 8.48 (8.42–8.54) 9.45 (9.37–9.53) 
pH 7.30 9.81 (9.39–10.24) 8.79 (8.73–8.85) 9.67 (9.31–10.02) 
pH 7.20 N/A 9.09 (9.01–9.17) N/A 
1
 Shown are pH50 values and 95% confidence intervals in brackets. 
 
 
 
Table 3 
  
Summary of wild-type and mutant PcTx1 IC50 values on rat and human ASIC1a 
  Human   Rat
1
 
 IC50 (nM) pIC50 
(95% CI) 
P value
2
  IC50 (nM) pIC50 
(95% CI) 
P value
2
 
WT 3.14 8.50 
(8.41–
8.60) 
–  0.35 9.45 
(9.34–
9.55) 
– 
N2 22.4 7.65 
(7.51–
7.78) 
0.0001  0.47 9.33 
(9.18–
9.47) 
0.9995 
K6A >1000 N/A 0.0001  34.2 7.47 
(6.96–
7.98) 
0.0001 
W7A >1000 N/A 0.0001  >1000 N/A 0.0001 
K8A 5.23 8.28 
(8.18–
8.38) 
0.2676  0.59 9.23 
(9.13–
9.33) 
0.9991 
H14A 4.31 8.37 
(8.22–
8.50) 
0.7897  0.26 9.62 
(9.49–
9.76) 
0.9994 
W24A >1000 N/A 0.0001  90.6 7.04 
(6.46–
7.63) 
0.0001 
K25A 4.98 8.32 
(8.14–
8.46) 
0.5242  0.64 9.19 
(9.10–
9.29) 
0.9991 
R26A
3
 164 6.79 
(6.25–
7.01) 
0.0001  1880 N/A 0.0001 
R27A 33.1 7.48 
(7.42–
7.54) 
0.0001  3.01 8.52 
(8.46–
8.59) 
0.2000 
R28A 106 6.98 
(6.84–
7.07) 
0.0001  5.06 8.30 
(8.23–
8.36) 
0.0293 
S29A 3.30 8.48 
(8.40–
8.56) 
0.9997  0.32 9.49 
(9.45–
9.53) 
0.9999 
F30A3 25.6 7.59 
(6.97–
8.22) 
0.0001  6.79 8.17 
(7.55–
8.79) 
0.0208 
E31A 3.00 8.52 
(8.42–
8.62) 
0.9997  0.76 9.12 
(9.07–
9.17) 
0.9948 
  
V32A 63.3 7.20 
(6.83–
7.39) 
0.0001  6.27 8.20 
(8.13–
8.28) 
0.0589 
V34A 2.09 8.68 
(8.54–
8.82) 
0.4592  0.49 9.31 
(9.17–
9.45) 
0.9995 
P35A 4.24 8.37 
(8.26–
8.48) 
0.9445  0.13 9.89 
(9.84–
9.95) 
0.8977 
K36A 4.99 8.30 
(8.24–
8.37) 
0.3038  0.19 9.72 
(9.66–
9.79) 
0.9957 
T37A 7.69 8.11 
(8.05–
8.18) 
0.0033  0.25 9.60 
(9.48–
9.72) 
0.9995 
P38A 10.8 7.97 
(7.80–
8.13) 
0.0001  1.36 8.86 
(8.74–
8.99) 
0.6950 
C3 8.77 8.06 
(7.96–
8.15) 
0.0005  1.44 8.84 
(8.74–
8.93) 
0.4434 
1
 Values for rat ASIC1a not from this study are from [18, 19], 
#
 
2
 P values are compared to WT PcTx1 for each species variant and bold indicates a significant 
difference (P < 0.01). 
3
 Mutants that potentiate channel and values indicate EC50.  
 
 
 
 
 
 
 
Table 4 
Summary of wild-type and mutant PcTx1 pIC50 values on rat ASIC1a and ASIC1b 
 rASIC1a  rASIC1b 
  
 pIC50 (95% CI) P value  pIC50 (95% CI) P value 
WT 9.05 (8.98–9.14) –  7.61 (7.40–7.82) – 
 9.14 (9.03–9.26) 0.2090  7.37 (7.11–7.62) 0.1341 
T37A 9.27 (8.99–9.49) 0.1694  7.63 (7.34–8.01) 0.8923 
K25A/T37A
1
 9.02 (8.94–9.12) 0.5466  7.00 (6.57–7.43) 0.0108 
W24A 6.72 (6.35–6.93) 0.0001  N/A N/A 
W24F 6.64 (6.40–6.84) 0.0001  6.76 (6.48–6.97) 0.2601 
W24Y 7.50 (7.22–7.79) 0.0001  7.28 (7.11–7.44) 0.0166 
R28H 9.06 (8.92–9.20) 0.9697  7.44 (7.13–7.78) 0.3912 
 
 
  
  
 
